Company Overview: Bioline RX Ltd.


Industry News

21 Nov

BioLineRx Reports Third Quarter 2017 Financial Results

TEL AVIV, Israel, Nov. 21, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017. Highlights and achievements during the third quarter 2017 and to date: Continued execution on multiple clinical development studies for BL-8040,...

Read more

20 Nov

BioLineRx Announces Partial Results of BL-8040 COMBAT Study Accepted for Presentation at ASCO 2018 Gastrointestinal Cancers Symposium

Enrollment to COMBAT study has been completed; full topline results expected in H2 2018 as planned TEL AVIV, Israel, November 20, 2017 /PRNewswire/ — BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that an abstract with partial results from the monotherapy portion of BL-8040’s...

Read more

16 Nov

BioLineRx Ltd. to Host Investor Breakfast Meeting December 5, 2017 in New York

TEL AVIV, Israel, November 16, 2017 /PRNewswire/ — BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will host an investor breakfast meeting on Tuesday, December 5, 2017 at the Convene Conference Center near Grand Central in New York, NY. The agenda and topics for discussion...

Read more

9 Nov

BioLineRx to Report Third Quarter 2017 Results on November 21, 2017

Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel, November 9, 2017 /PRNewswire/ — BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended September 30, 2017 on Tuesday, November 21, 2017, before...

Read more

6 Nov

BioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term Engraftment

– Preclinical data demonstrate that BL-8040 mobilizes a significant number of these HSCs compared to G-CSF, thus potentially improving graft quality – TEL AVIV, Israel, November 2, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, disclosed today preclinical data of BL-8040, its lead oncology...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address